AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Poxel Announces its Financial Calendar for 2020

January 8, 2020 GMT

LYON, France--(BUSINESS WIRE)--Jan 8, 2020--

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its calendar for the publication of financial information for 2020.

Event

Date*

2019 Fourth Quarter Financial Update

February 12, 2020

2019 Annual Results

March 26, 2020

2020 First Quarter Financial Update

April 21, 2020

2020 Second Quarter Financial Update

July 21, 2020

2020 First Half Results

September 15, 2020

2020 Third Quarter Financial Update

October 20, 2020

2020 Fourth Quarter Financial Update

February 11, 2021

*Subject to modification

All corporate information on Poxel, such as its financial statements, press releases or its corporate presentations, is available on the Company’s website in the “ Investors ” section.

About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel successfully completed the Phase 3 T rials of IM eglimin for E fficacy and S afety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005955/en/

CONTACT: Poxel SA

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

+1 617 818 2985Aurélie Bozza

Investor Relations and Communication Director

aurelie.bozza@poxelpharma.com

+33 6 99 81 08 36Investor relations / Media - EU/US

Trophic Communications

Stephanie May or Joanne Tudorica

may@trophic.euortudorica@trophic.eu

+49 89 238 877 34 or +49 171 185 56 82Investor relations / Media - France

NewCap

Alexia Faure or Arthur Rouillé

poxel@newcap.eu

+33 1 44 71 94 94

KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA FRANCE

INDUSTRY KEYWORD: RESEARCH FDA DIABETES BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE

SOURCE: Poxel SA

Copyright Business Wire 2020.

PUB: 01/08/2020 02:00 AM/DISC: 01/08/2020 02:01 AM

http://www.businesswire.com/news/home/20200107005955/en